Comparative Pharmacology
Head-to-head clinical analysis: LEVOLET versus RECORLEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOLET versus RECORLEV.
LEVOLET vs RECORLEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levolet (levothyroxine) is a synthetic thyroid hormone that replaces endogenous thyroxine (T4). It is converted to triiodothyronine (T3) in peripheral tissues, which binds to thyroid hormone receptors to regulate gene expression, increasing metabolic rate and protein synthesis.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
Levofloxacin 500 mg orally or intravenously once daily for 5-14 days depending on indication.
150 mg orally twice daily with a high-fat meal.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; shorter in patients with hepatic impairment.
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
Renal: 70-80% unchanged, biliary/fecal: 20-30% as metabolites.
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Category C
Category C
Thyroid Hormone
Thyroid Hormone